K. Blyth (Glasgow (Glasgow), United Kingdom), C. Koegelenberg (Cape Town, South Africa), A. West (London, United Kingdom), M. Froudarakis (Alexandroupolis, Greece)
Single-center prospective study on clinical evolution of non-specific pleuritis
F. Mei (Ancona, Italy), M. Bonifazi (Ancona, Italy), L. Zuccatosta (Ancona, Italy), F. Barbisan (Ancona, Italy), M. Sediari (Ancona, Italy), S. Gasparini (Ancona, Italy)
|   |
The clinical benefits of immune checkpoint inhibitors for thymic carcinomas
N. Uchida (Kyoto, Japan), K. Fujita (Kyoto, Japan), O. Kanai (Kyoto, Japan), M. Okamura (Kyoto, Japan), K. Nakatani (Kyoto, Japan), T. Mio (Kyoto, Japan)
| |
The Role of PET-CT in differential diagnosis of malignant-paramalignant pleural effusion
E. Torun Parmaksiz (Istanbul, Turkey), B. Akkurt (Istanbul, Turkey), C. DogAn (Istanbul, Turkey), S. Beyhan SagMen (Istanbul, Turkey), N. KiRal (Istanbul, Turkey), S. CöMert (Istanbul, Turkey), A. Fidan (Istanbul, Turkey), S. Akkus (Istanbul, Turkey)
| |
Determinants of survival in patients with malignant pleural mesothelioma (MPM) managed at a single institution in Liguria, Italy
A. Carletti (Sarzana, Italy), L. Benfatto (Genova, Italy), V. Balestracci (Sarzana, Italy), P. Canessa (Sarzana, Italy)
| |
Predictors of pleurodesis success
R. Mercer (Oxford, United Kingdom), N. Speck (Zurich, Switzerland), H. Jeffries (Oxford, United Kingdom), J. Macready (Oxford, United Kingdom), N. Kanellakis (Oxford, United Kingdom), N. Maskell (Bristol, United Kingdom), J. Pepperell (Taunton, United Kingdom), T. Saba (Blackpool, United Kingdom), A. West (London, United Kingdom), N. Ali (Mansfield, United Kingdom), R. Miller (London, United Kingdom), J. Corcoran (Oxford, United Kingdom), R. Asciak (Oxford, United Kingdom), M. Hassan (Oxford, United Kingdom), R. Hallifax (Oxford, United Kingdom), I. Psallidas (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom)
| |
The patient perspective of treatment for Malignant Pleural Effusion (MPE)- results of a pilot service-evaluation questionnaire.
J. Seymour (Oxford, United Kingdom), I. Psallidas (Oxford, United Kingdom), M. Dobson (Oxford, United Kingdom), N. Rahman (Oxford, United Kingdom)
| |
ANALYSIS OF INITIAL NON-CONCLUSIVE THORACOSCOPIES WITH A DIAGNOSIS OF MALIGNANCY OBTAINED DURING LONG-TERM FOLLOW-UP OF RECURRENT EXUDATIVE PLEURAL EFFUSIONS
L. Padron Fraysse (Huelva, Spain), B. Romero Romero (Sevilla, Spain), F. Rodriguez Panadero (Sevilla, Spain), J. Martin Juan (Sevilla, Spain)
| |
Clinical and histological analysis of malignant mesothelioma - a comprehensive state-wide study
N. Pferdmenges (Muenster, Germany), V. Krieg (Muenster, Germany), A. Schulze (Muenster, Germany), H. Kajueter (Muenster, Germany), G. Evers (Muenster, Germany), M. Mohr (Muenster, Germany), L. Schmidt (Muenster, Germany), H. Hense (Muenster, Germany), O. Heidinger (Muenster, Germany), R. Wiewrodt (Muenster, Germany)
| |
Iodopovidone pleurodesis, diferent techniques, excellent efficacy in malignant pleural effusion.. Tanta University experience
R. Sharshar (Tanta, Egypt)
| |
Is there a need for Vedio-assisted Thoracoscopic surgical (VATS) pleural biopsy following a Medical Thoracoscopy (MT)?
M. Abdulla (Chesterfield, United Kingdom), J. Hadfield (Chesterfield, United Kingdom), T. Aung (Chesterfield, United Kingdom), A. El-Nayal (Chesterfield, United Kingdom)
| |
US guided true cut needle biopsy in patients with malignant mesothelioma
R. Petkov (Sofia, Bulgaria), T. Mihalova (Sofia, Bulgaria), Y. Yamakova (Sofia, Bulgaria), G. Yankov (Sofia, Bulgaria)
| |
Relationship between baseline metabolic 18F-FDG parameters and survival in malignant pleural mesothelioma: A single centre experience
Y. Kahya (Ankara, Turkey), Ç. Soydal (Ankara, Turkey), M. Yenigün (Ankara, Turkey), E. Özkan (Ankara, Turkey), N. Ata Tutkun (Ankara, Turkey), S. Enön (Ankara, Turkey), N. Küçük (Ankara, Turkey), A. Kayi Cangir (Ankara, Turkey)
| |
A comparison of outcomes from a regional Mesothelioma MDT against the National Lung Cancer Audit (NLCA) Mesothelioma standards
M. Ahmed (Manchester, United Kingdom), J. Lyons (Manchester, United Kingdom), S. Jackson (Manchester, United Kingdom), A. Sharman (Manchester, United Kingdom), M. Dixon (Manchester, United Kingdom), P. Taylor (Manchester, United Kingdom), J. Holme (Manchester, United Kingdom), M. Evison (Manchester, United Kingdom)
| |
Survival of patients with malignant pleural effusions: a three-year prospective self-experience study
I. Novakov (Plovdiv, Bulgaria), F. Sterev (Plovdiv, Bulgaria)
| |
Assessing breathlessness following pleural fluid drainage using the Visual Analogue Scale for Dyspnoea(VASD) over 1 week(7-DVQ)
R. Banka (Norwich, United Kingdom), E. Mishra (Norwich, United Kingdom)
| |
EBUS-TBNA for the diagnosis of intrathoracic lymphadenopathy in patients with previously diagnosed breast carcinoma
N. Piskac Živkovic (Zagreb, Croatia), A. Ljilja (Zagreb, Croatia), N. Novak (Zagreb, Croatia), N. Tudoric (Zagreb, Croatia)
| |
Evaluation of chemotherapy response determined by volumetric method in malignant pleural mesothelioma and its effect on determination to survival
F. Urfali (Sakarya, Turkey), S. Metintas (Eskisehir, Turkey), A. Gurgen (Erzurum, Turkey), G. Ak (Eskisehir, Turkey), R. Ozkan (Manisa, Turkey), M. Metintas (Eskisehir, Turkey)
| |
Cisplatin/pemetrexed chemotherapy versus palliative care survival in malignant pleural mesothelioma
I. Škopljanac (Split, Croatia), I. Segrt (Split, Croatia), K. Mise (Split, Croatia), E. Lozo Vukovac (Split, Croatia), A. Tolic Biocina (Split, Croatia)
| |
Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells
E. Papazoglou (Larissa, Greece), R. Jagirdar (Larissa, Greece), E. Pitaraki (Larissa, Greece), O. Kotsiou (Larissa, Greece), C. Hatzoglou (Larissa, Greece), K. Gourgoulianis (Larissa, Greece), S. Zarogiannis (Larissa, Greece)
| |